PETRI DISH PERSPECTIVES

PETRI DISH PERSPECTIVES

Download on the App Store

PETRI DISH PERSPECTIVES episodes

  • Episode 13: Sarepta

    Send us Fan Mail

    DISCLAIMER: This is a consistently changing situation. The episode was recorded approximately 4 PM EDT Monday, July 21, 2025.Ā  As of 7.40 PM EDT Monday, July 21, 2025 (Source: Sarepta), "Sarepta Therapeutics notified the U.S. FDA of its decision to voluntarily and temporarily pause all shipments of ELEVIDYS (delandistrogene moxeparvovec) for Duchenne muscular dystrophy in the United States, effective close of business Tuesday, July 22, 2025."

    šŸŽ™ļø When Hope Collides with Risk: Sarepta’s Gene Therapy Crisis

    In this episode of Petri Dish Perspectives,Ā  Manead goes off-script to unpack one of the hottest biotech stories in the headlines today: the unraveling of Sarepta Therapeutics.

    What began in a small Oregon lab in 1980 as Antivirals Inc. evolved into Sarepta, a pioneer in the fight against Duchenne muscular dystrophy (DMD). From early exon-skipping breakthroughs to the dazzling promise of its gene therapy, Elevidys, Sarepta has long been a symbol of hope for families facing an otherwise devastating disease.

    But in 2025, that hope hit a hard wall: patient deaths, regulatory clashes, and a growing crisis that’s shaking confidence in gene therapy as a whole. In under 30 minutes, Manead breaks down Sarepta’s 40-year journey, the science, the promise, the standoff with the FDAĀ  and what this turning point means for the future of genetic medicine.

    This isn’t just another biotech update, it’s a raw look at what happens when cutting-edge hope meets the harsh edge of reality.

    Grab your coffee or tea, hit play, and stay curious.

    šŸŽ§ Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!

    https://linktr.ee/maneadkhin

    #Biotech #GeneTherapy #Sarepta #DMD #FDA #RareDisease #PetriDishPerspectives #BiotechUnleashed

    Support the show

    Ā© 2026 The Perspective Bureau LLC. All rights reserved.

    24 min
  • Episode 12: Vertex

    Send us Fan Mail

    šŸ”¬āœØ From Cystic Fibrosis Breakthroughs to Gene Editing Cures

    In this episode of Petri Dish Perspectives: Biotech Unleashed, Manead unpacks how Vertex turned cystic fibrosis from a fatal disease into a treatable condition and why they’re now tackling sickle cell, diabetes, and more with CRISPR and stem cell science.

    Discover how visionary chemists, Nobel-winning gene editors, and patient advocates built one of biotech’s most inspiring success stories, proving that deep science and real patient impact can go hand in hand.

    Grab your coffee and hit play! šŸš€

    šŸŽ§ Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!

    https://linktr.ee/maneadkhin

    #Biotech #VertexPharma #CRISPR #GeneEditing #CysticFibrosis #RareDisease #HealthcareInnovation #PetriDishPerspectives #BiotechPodcast

    Support the show

    Ā© 2026 The Perspective Bureau LLC. All rights reserved.

    25 min
  • Episode 11: Genentech

    Send us Fan Mail

    🧬 From VC to Blockbusters: The Genentech Story
    In Episode 11 of Petri Dish Perspectives: Biotech Unleashed, host Manead dives into the legendary rise of Genentech, the startup that sparked the biotech revolution. From its humble beginnings in a borrowed lab to pioneering insulin, tPA, Herceptin, and more, learn how Genentech turned recombinant DNA into real-world cures. Discover the bold VC bets, game-changing antibodies, and the Roche acquisition that preserved its science-first culture. A must-listen for biotech nerds and curious minds alike!

    šŸŽ§ Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!

    https://linktr.ee/maneadkhin

    #Genentech #BiotechPodcast #Herceptin #Avastin #Rituxan #RecombinantDNA #OncologyInnovation #PetriDishPerspectives #HealthcareInnovation #PharmaHistory #RocheGroup #StartupToSuperpower

    Support the show

    Ā© 2026 The Perspective Bureau LLC. All rights reserved.

    27 min
  • Episode 10: Roche

    Send us Fan Mail

    šŸ’” From Vitamin C to AI-Driven Diagnostics: Roche’s Legacy Unleashed
    In this episode of Petri Dish Perspectives: Biotech Unleashed, we explore the extraordinary evolution of Roche, from its origins as a 19th-century Swiss chemical company to becoming a global leader in pharmaceuticals and diagnostics.

    You’ll hear how Roche launched the world’s first branded vitamin C, pioneered molecular diagnostics with PCR, and laid the groundwork for today’s precision medicine revolution. We’ll also dive into how Roche’s unique dual-engine model—drugs + diagnostics, that helped shape modern healthcare.

    Whether you're a biotech nerd or just curious about the science behind your health, this episode is packed with insight, history, and a glimpse into Roche’s future.

    šŸŽ§ Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!

    https://linktr.ee/maneadkhin

    #Roche #Biotech #Diagnostics #VitaminC #PCR #PrecisionMedicine #HealthcareInnovation #PharmaGiants #PetriDishPerspectives #BiotechPodcast

    Support the show

    Ā© 2026 The Perspective Bureau LLC. All rights reserved.

    21 min
  • Episode 9: Bayer

    Send us Fan Mail

    šŸŽ§ From Dye Pots to Blockbusters: The Bayer Story
    In this episode of Petri Dish Perspectives: Biotech Unleashed, host Manead takes you on a journey through Bayer’s 160+ year evolution, from its 1863 roots in coal tar dyes to becoming the maker of Aspirin šŸ’Š, Xarelto ā¤ļø, and Eylea šŸ‘ļø. We explore how a dye salesman and a master dyer built a pharma empire, the game-changing invention of Aspirin, blockbuster therapies, the turbulent Monsanto acquisition šŸŒ¾āš–ļø, and the company’s high-stakes reinvention under CEO Bill Anderson.

    🧬 Science, strategy, and resilience — Bayer’s story is biotech history in motion.

    šŸŽ™ļø Tune in for a 30-min deep dive into one of the world’s most iconic life science companies.

    šŸŽ§ Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!

    https://linktr.ee/maneadkhin

    #Bayer #Biotech #PetriDishPerspectives #BiotechPodcast #ScienceStorytelling #BillAnderson #HealthcareLeadership

    Support the show

    Ā© 2026 The Perspective Bureau LLC. All rights reserved.

    17 min
  • Episode 8: Bristol Myers Squibb

    Send us Fan Mail

    In this episode of Petri Dish Perspectives: Biotech Unleashed, we journey through the 165+ year saga of Bristol Myers Squibb (BMS) — from 19th-century Brooklyn apothecaries and sparkling laxatives šŸ’Š to cutting-edge CAR-T therapies and checkpoint inhibitors in cancer treatment šŸ§«šŸ”„.

    Host Manead, a PhD scientist in cancer biology and analytical chemistry, breaks down:

    šŸ“œ The parallel founding stories of E.R. Squibb & Sons and Bristol-Myers
     🧠 The game-changing 1989 merger that created BMS
    Ā ā¤ļø Blockbuster hits in cardiovascular health (Plavix, anyone?)
     🧪 The leap into immuno-oncology with Opdivo and Yervoy
    🧲 The bold $74B acquisition of Celgene — and how it supercharged BMS’s cell therapy pipeline
    šŸš€ What’s next in AI-driven R&D, off-the-shelf CAR-Ts, and more

    If you’re curious how a legacy pharma reinvented itself into an oncology and biotech juggernaut, this episode is for you.

    Grab your favorite drink and tune in to explore the science, the strategy, and the standout leaders behind BMS.

    šŸŽ§ Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!

    https://linktr.ee/maneadkhin

    #PetriDishPerspectives #BiotechUnleashed #BMS #Immunotherapy #CAR_T #PharmaHistory #Oncology #BiotechPodcast

    Support the show

    Ā© 2026 The Perspective Bureau LLC. All rights reserved.

    15 min
  • Episode 7: Sanofi

    Send us Fan Mail

    Ever wonder how an oil conglomerate helped create one of the world’s top pharma giants? šŸ’„ In this episode of Petri Dish Perspectives: Biotech Unleashed, your host, Manead, dives into the fascinating story of Sanofi, a company whose name you’ve probably seen on insulin pens šŸ’‰, flu shots 🦠, and blockbuster immunology meds šŸ’Š.

    We explore:
    Ā šŸ”¹ Sanofi’s wild beginnings inside a French oil giant šŸ›¢ļø
    Ā šŸ”¹ Game-changing acquisitions — Aventis, Genzyme, and more šŸ’ø
    Ā šŸ”¹ Lantus and its dominance in diabetes care 🧃
    Ā šŸ”¹ Vaccine legacy from Louis Pasteur to COVID-19 🧫
    Ā šŸ”¹ The Dupixent boom and Regeneron partnership šŸ¤
    Ā šŸ”¹ Bold bets on mRNA 🧬 and AI šŸ” in drug discovery
    Ā šŸ”¹ CEO Paul Hudson’s tech-first transformation šŸš€

    Whether you’re into biotech strategy, pharma history, or future-forward science, this 30-minute episode has something for every science nerd and healthcare junkie out there šŸ”¬šŸ’”

    Grab your favorite drink, hit play, and geek out with us!

    šŸŽ§ Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!

    https://linktr.ee/maneadkhin

    #biotech #pharma #Sanofi #healthcareinnovation #podcast #PetriDishPerspectives

    Support the show

    Ā© 2026 The Perspective Bureau LLC. All rights reserved.

    13 min
  • Episode 6: Merck

    Send us Fan Mail

    In this episode of Petri Dish Perspectives: Biotech Unleashed, we'll take you on a 350-year journey through the rise of Merck, from its humble beginnings as a family-run pharmacy in 17th-century Germany to becoming one of the world’s most influential pharmaceutical powerhouses.

    We’ll explore how Merck evolved through groundbreaking discoveries like streptomycin, the MMR vaccine, statins, and the game-changing cancer immunotherapy Keytruda. You’ll also hear about the incredible legacy of Dr. Maurice Hilleman, a vaccine pioneer whose work continues to save millions of lives today.

    Along the way, we dive into Merck’s unique split post-WWI, its relentless focus on science-first innovation, and its modern-day ventures in oncology, gene editing, and AI-driven drug discovery.

    Whether you’re a biotech enthusiast, healthcare professional, or just curious about the companies shaping tomorrow’s medicine, this episode packs powerful insights in under 30 minutes. Grab your coffee and settle in, this is Merck, unleashed.

    šŸŽ§ Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!

    https://linktr.ee/maneadkhin

    Support the show

    Ā© 2026 The Perspective Bureau LLC. All rights reserved.

    13 min
  • Episode 5: Boehringer Ingelheim

    Send us Fan Mail

    🐓 From Farmyard Roots to Pharma Powerhouse: The Boehringer Ingelheim Story 🐓

    Welcome to Petri Dish Perspectives: Biotech Unleashed! šŸš€ I’m your host, Manead—scientist and biotech nerd.

    Today, we’re spotlighting Boehringer Ingelheim—a family-owned pharma giant that began in a small German village and grew into one of the world’s top 20 pharmaceutical companies. From veterinary vaccines to life-saving treatments for respiratory disease, diabetes, and cancer, Boehringer has quietly shaped medicine for humans and animals alike.

    They’ve stayed private for over 135 years—what’s their secret? How did a rural chemist’s workshop become a global leader in immuno-oncology and regenerative medicine? And where is Boehringer placing its bets for the future?

    Grab your notebook—or your favorite biotech-friendly beverage—and join me as we explore the fascinating rise of Boehringer Ingelheim. šŸ’Š

    šŸŽ§ Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!

    https://linktr.ee/maneadkhin

    Support the show

    Ā© 2026 The Perspective Bureau LLC. All rights reserved.

    17 min
  • Episode 4: Johnson & Johnson

    Send us Fan Mail

    In this episode of Petri Dish Perspectives: Biotech Unleashed, we dive into the rich history and groundbreaking innovations of Johnson & Johnson (J&J)—one of the most influential healthcare companies in the world. From its origins in the late 19th century as a family-run surgical supply business to becoming a household name with products like Band-Aids, Tylenol, and Johnson’s Baby Powder, J&J has shaped modern medicine in countless ways.

    We’ll explore how Robert Wood Johnson I, alongside his brothers, turned a struggling startup into a global powerhouse by pioneering antiseptic surgical techniques, mass-market first-aid products, and cutting-edge medical devices. Along the way, we’ll also discuss J&J’s resilience through major challenges—like the 1982 Tylenol crisis, which redefined corporate crisis management.

    Fast forward to today, and J&J is still at the forefront of innovation, investing heavily in robotics, gene therapy, and AI-driven healthcare solutions.Ā 

    Grab a coffee and tune in for a fast-paced, insightful breakdown of J&J's journey!

    šŸŽ§ Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!

    https://linktr.ee/maneadkhin

    Support the show

    Ā© 2026 The Perspective Bureau LLC. All rights reserved.

    20 min

About PETRI DISH PERSPECTIVES

From the publisher's feed

Burma | Chicago
Scientist šŸ„¼šŸ§ŖšŸ”¬
Covering biotech, pharma, and healthcare companies shaping the world šŸ§¬šŸ„šŸŒŽ

Stream new episodes every…